Tech Company Financing Transactions
Bayhill Therapeutics Funding Round
On 4/10/2006, Bayhill Therapeutics raised $51.2 million in Series B financing from De Novo Ventures, Latterell Venture Partners and Lilly Ventures.
Transaction Overview
Company Name
Announced On
4/10/2006
Transaction Type
Venture Equity
Amount
$51,200,000
Round
Series B
Investors
Proceeds Purpose
This financing supports the development of our lead product candidate currently in phase I, BHT-3009, an antigen-specific drug for treating multiple sclerosis, through Phase II clinical testing.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
1804 Embarcadero Rd. 201
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Website
Email Address
Overview
Bayhill Therapeutics Inc. is focused on the translation of research into therapeutics by developing novel drugs for the treatment of autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Operating Officer
Hideki Garren
VP - Finance
Kwang Lee
VP - Manufacturing
Robert King
VP - Regulatory Affairs
Joanne Quan
Browse more venture capital transactions:
Prev: 4/10/2006: Uplogix venture capital transaction
Next: 4/11/2006: ShotSpotter venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs